Cargando…

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer

Acquired resistance to platinum (Pt)‐based therapies is an urgent unmet need in the management of epithelial ovarian cancer (EOC) patients. Here, we characterized by an unbiased proteomics method three isogenic EOC models of acquired Pt resistance (TOV‐112D, OVSAHO, and MDAH‐2774). Using this approa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lombardi, Rita, Sonego, Maura, Pucci, Biagio, Addi, Laura, Iannelli, Federica, Capone, Francesca, Alfano, Luigi, Roca, Maria Serena, Milone, Maria Rita, Moccia, Tania, Costa, Alice, Di Gennaro, Elena, Bruzzese, Francesca, Baldassarre, Gustavo, Budillon, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024727/ https://www.ncbi.nlm.nih.gov/pubmed/33331136 http://dx.doi.org/10.1002/1878-0261.12883

Ejemplares similares

Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
por: Milone, Maria Rita, et al.
Publicado: (2014)

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition
por: Iannelli, Federica, et al.
Publicado: (2020)

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid
por: Bizzarro, Valentina, et al.
Publicado: (2015)

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation
por: Ciardiello, Chiara, et al.
Publicado: (2019)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022)

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
por: Iannelli, Federica, et al.
Publicado: (2020)

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
por: Ciardiello, Chiara, et al.
Publicado: (2016)

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
por: Milone, M R, et al.
Publicado: (2013)

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
por: Milone, M R, et al.
Publicado: (2014)

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells
por: Sonego, Maura, et al.
Publicado: (2019)

Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
por: Cocco, Stefania, et al.
Publicado: (2022)

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Evaluation of Selenite Effects on Selenoproteins and Cytokinome in Human Hepatoma Cell Lines
por: Rusolo, Fabiola, et al.
Publicado: (2013)

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells
por: Lorenzon, Ilaria, et al.
Publicado: (2019)

A new role for IDH1 in the control of ovarian cancer cells metabolism and senescence
por: Sonego, Maura, et al.
Publicado: (2020)

An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer
por: Costantini, Susan, et al.
Publicado: (2022)

Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity
por: Pellarin, Ilenia, et al.
Publicado: (2020)

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
por: Sonego, Maura, et al.
Publicado: (2017)

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
por: Bruzzese, F, et al.
Publicado: (2013)

Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
por: Roca, Maria Serena, et al.
Publicado: (2019)

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
por: Dall'Acqua, Alessandra, et al.
Publicado: (2017)

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

The druggable genome: Twenty years later
por: Radoux, Chris J., et al.
Publicado: (2022)

In Silico Insights towards the Identification of NLRP3 Druggable Hot Spots
por: Mekni, Nedra, et al.
Publicado: (2019)

Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

HSP90AB1 as the Druggable Target of Maggot Extract Reverses Cisplatin Resistance in Ovarian Cancer
por: Wang, Daojuan, et al.
Publicado: (2023)

Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic Profiles
por: Sorice, Angela, et al.
Publicado: (2016)

Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment
por: Meo, Concetta, et al.
Publicado: (2023)

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer
por: Capone, Francesca, et al.
Publicado: (2020)

Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer †
por: Costantini, Susan, et al.
Publicado: (2021)

USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability
por: Sonego, Maura, et al.
Publicado: (2019)

The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells
por: Colangelo, T, et al.
Publicado: (2016)

KRAS: A Druggable Target in Colon Cancer Patients
por: Negri, Francesca, et al.
Publicado: (2022)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells
por: Ranzuglia, Valentina, et al.
Publicado: (2020)

Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex
por: Evans, Lindsay E., et al.
Publicado: (2017)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

The Druggable Pocketome of Corynebacterium diphtheriae: A New Approach for in silico Putative Druggable Targets
por: Hassan, Syed S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nngsht4h5gcied82uc6ph7t1i2